TABLE 2

Effects of des-fluoro-sitagliptin and glipizide on plasma parameters in the HFD/STZ mouse model

A1C (%)GLP-1intact (pmol/l)Glucagon (pg/ml)Triglyceride (mg/dl)FFA (mmol/l)
Vehicle7.5 ± 0.22.1 ± 0.492 ± 14400 ± 353.4 ± 0.4
Des-fluoro-sitagliptin5.6 ± 0.3*9.9 ± 3.4*51 ± 6*196 ± 32*1.3 ± 0.2*
Glipizide7.2 ± 0.21.8 ± 0.5100 ± 15322 ± 432.4 ± 0.3
Nondiabetic control4.5 ± 0.1*1.9 ± 0.452 ± 4*110 ± 10*0.6 ± 0.1*
  • Data are means ± SE (n = 8–10). Nondiabetic control mice or diabetic HFD/STZ mice were treated with HFD containing vehicle, des-fluoro-sitagliptin (1.1% admixture), or glipzide (0.02% admixture) for 10 weeks. A1C, plasma GLP-1, glucagon, triglycerides, and FFAs (FFA levels were measured under the fed condition).

  • *

    * P < 0.05 compared with the vehicle-treated group.